Munich - Delayed Quote EUR

Optinose Inc. R (0OP0.MU)

8.15

0.00

(0.00%)

As of 8:08:07 AM GMT+2. Market Open.

Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More

SAVA and ALNY are in the spotlight this week following a study failure and label expansion of lead drug, respectively.

Zacks 29 days ago

SAVAW

ALNY

OPTN
OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates

OptiNose (OPTN) delivered earnings and revenue surprises of 95.71% and 5.57%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 29 days ago

OPTN
OptiNose: Q4 Earnings Snapshot

YARDLEY, Pa. AP) — OptiNose Inc. OPTN) on Wednesday reported a loss of $360,000 in its fourth quarter.

Associated Press Finance 29 days ago

OPTN
Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

Company reports fourth quarter and full year 2024 XHANCE net revenue of $22.4 million and $78.2 million, increases of 13% and 10% compared to prior year periods Company reports 23% prescription growth from third quarter 2024 to fourth quarter 2024 YARDLEY, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended Decembe

GlobeNewswire 29 days ago

OPTN
Wall Street Analysts Believe OptiNose (OPTN) Could Rally 143.06%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 143.1% in OptiNose (OPTN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks last month

OPTN
OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek

OptiNose stock surges 53% as it is set to be acquired by Paratek for $330 million, adding chronic rhinosinusitis drug, Xhance, to the latter's portfolio.

Zacks last month

OPTN
Why OptiNose Inc. (OPTN) Surged On Thursday?

We recently published a list of 10 Micro-, Small-Cap Firms Dominate Thursday’s Gains. In this article, we are going to take a look at where OptiNose Inc. (NASDAQ:OPTN) stands against other micro-, small-cap firms that dominate Thursday’s gains. The stock market edged lower on Thursday, erasing gains from the previous trading day that was buoyed […]

Insider Monkey last month

OPTN
OptiNose Surges Premarket Following Acquisition Agreement With Paratek Pharmaceuticals for Up to $330 Million

OptiNose (OPTN) shares were up more than 61% in premarket activity Thursday after the company overni

PREMIUM
MT Newswires last month

OPTN
Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time. The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement

GlobeNewswire last month

OPTN
OptiNose (NASDAQ:OPTN) shareholders have endured a 90% loss from investing in the stock five years ago

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...

Simply Wall St. last month

OPTN
Optinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial Results

Conference Call and Webcast to be held March 20, 2025, at 8:00 a.m. Eastern TimeYARDLEY, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the fourth quarter and full year of 2024 and corporate updates, before market open, on Thursday, March 20, 2025. Company to Host Conference CallMembers of the Company’s leadersh

GlobeNewswire last month

OPTN
Optinose price target adjusted for stock split at Lake Street

Lake Street analyst Thomas Flaten lowered the firm’s price target on Optinose (OPTN) to $17 from $45 and keeps a Buy rating on the shares, saying that “in part accounting for the recent 1-for-15 reverse stock split, we revised our $3 price target to $17″ after OptiNose delivered preliminary XHANCE revenue for Q4 of $22.4M, which was above the firm’s and consensus estimates. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top

TipRanks 3 months ago

OPTN
Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million

Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20%YARDLEY, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced preliminary unaudited XHANCE® (fluticasone propionate) net product revenue of $22.4 million for the three months ended December 31, 2024. “Our preliminary unaudited fourth quarter net p

GlobeNewswire 3 months ago

OPTN

Performance Overview

Return	0OP0.MU	S&P 500 (^GSPC)
YTD	+40.76%	-7.40%
1-Year	-40.29%	+7.38%
3-Year	-73.06%	+27.49%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Optinose Inc. R (0OP0.MU)

Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More

OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates

OptiNose: Q4 Earnings Snapshot

Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

Wall Street Analysts Believe OptiNose (OPTN) Could Rally 143.06%: Here's is How to Trade

OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek

Why OptiNose Inc. (OPTN) Surged On Thursday?

OptiNose Surges Premarket Following Acquisition Agreement With Paratek Pharmaceuticals for Up to $330 Million

Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

OptiNose (NASDAQ:OPTN) shareholders have endured a 90% loss from investing in the stock five years ago

Optinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial Results

Optinose price target adjusted for stock split at Lake Street

Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million

Performance Overview